Zynlonta Disease Interactions
There are 2 disease interactions with Zynlonta (loncastuximab tesirine).
Loncastuximab tesirine (applies to Zynlonta) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Patients with mild hepatic impairment should be monitored for a potential increase of adverse effects when using loncastuximab tesirine. This drug has not been studied in patients with moderate or severe hepatic impairment.
Loncastuximab tesirine (applies to Zynlonta) kidney disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The effects of severe renal impairment and end-stage renal disease in the pharmacokinetics of loncastuximab tesirine is unknown.
Switch to professional interaction data
Zynlonta drug interactions
There are 527 drug interactions with Zynlonta (loncastuximab tesirine).
Report options
More about Zynlonta (loncastuximab tesirine)
- Zynlonta consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or relapsed ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Columvi
Columvi is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
